JW Pharmaceutical said Thursday that it has launched a reduced-size version of its high-dose ibuprofen nonsteroidal anti-inflammatory drug (NSAID), Pain Angel Ibu Soft Cap, to make it more convenient.
Pain Angel Ibu is a high-dose pain reliever that contains 400 mg of ibuprofen per tablet.
According to JW Pharm, ibuprofen is recognized as a safe ingredient that provides fast pain relief with a low risk of gastrointestinal side effects and liver toxicity. Pain Angel Ibu is effective for fever, back pain, menstrual cramps, toothache, muscle pain, and pain caused by various conditions such as rheumatoid arthritis, acute gout, and soft tissue injuries.
In addition to Pain Angel Ibu, JW Pharmaceutical has a lineup of five anti-inflammatory pain relievers. The four other lineups are Pain Angel Pro (dexibuprofen), Pain Angel Xen (naproxen), Pain Angel Lady (ibuprofen, pamabrom), and Brapin S (ibuprofen).
The improvements to Pain Angel Ibu follow those of Pain Angel Pro in October and Brapin S in December, which focused on reducing the formulation size to make it more convenient.
With these improvements, Pain Angel Ibu's formulation size has been reduced to 16.6 mm wide and 10.0 mm long from 20.4 mm wide and 10.1 mm long.
In addition, the package design was changed from a horizontal to a vertical design to add differentiation.
JW Pharm plans to extend the improvement to Pain Angel Xen and Pain Angel Lady, continuously reducing the formulation size for the entire lineup of anti-inflammatory drugs.
"Pain Angel Ibu is an anti-inflammatory analgesic with a high content that provides quick pain relief and can be used for various indications," a JW Pharmaceutical official said. "We plan to strengthen our marketing activities with the existing lineup of Pain Angel analgesics by reducing the size of the formulation."
Related articles
- JW Pharmaceutical, Theraject Asia to advance microneedle hair loss treatment
- JW Pharmaceutical hit with record-high fine for illegal rebates
- JW Pharmaceutical’s hair loss treatment wins state new drug project
- JW Pharmaceutical's operating profit jumps 58% in 2023
- JW Shinyak to co-develop CAR-NK cell therapy with C&C Research Lab, KURE AI